See how it's done: GSK beats data access path
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline, now the industry leader on the clinical trial transparency front, has given more details of its system for providing raw patient-level data to researchers for further analysis, including strict controls over who can access the data and to what end. It has also named the members of the panel that will vet research proposals.